Opendata, web and dolomites

SMA-TB SIGNED

A novel Stratified Medicine Algorithm to predict treatment responses to host-directed therapy in TB patients.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 SMA-TB project word cloud

Explore the words cloud of the SMA-TB project. It provides you a very rough idea of what is the project "SMA-TB" about.

length    decrease    predicting    thanks    differ    add    pathogen    mathematical    science    outcomes    health    tb    anti    therapy    tissue    hyperinflammation    integrating    personalize    damage    directed    disease    effect    relevance    infectious    threatening    costly    stratifying    world    intervention    bad    protocol    clinically    benefit    potentially    resistance    medical    infective    stratify    hdt    ds    forms    clinical    life    poses    generate    medicine    cure    ct    personalized    susceptibility    validate    stages    aspirin    highest    faster    tremendous    mdr    resistant    drug    risk    therapies    predict    regimen    biomarkers    generating    severity    trials    tuberculosis    shorten    individualized    treatment    sequelae    data    patients    standard    sensitive    responsible    lung    chronic    host    prevalence    therapeutic    worse    reduce    inflammatory    strain    region    permanent    course    adjunct    algorithm    network    sma    physicians   

Project "SMA-TB" data sheet

The following table provides information about the project.

Coordinator
INSTITUT DE INVESTIGACIO EN CIENCIES DE LA SALUT GERMANS TRIAS I PUJOL 

Organization address
address: CTRA DE CANYET S/N
city: BADALONA BARCELONA
postcode: 8916
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Total cost 6˙388˙104 €
 EC max contribution 6˙388˙104 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SC1-2019-Two-Stage-RTD
 Funding Scheme RIA
 Starting year 2020
 Duration (year-month-day) from 2020-01-01   to  2024-06-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    INSTITUT DE INVESTIGACIO EN CIENCIES DE LA SALUT GERMANS TRIAS I PUJOL ES (BADALONA BARCELONA) coordinator 1˙632˙750.00
2    WITS HEALTH CONSORTIUM (PTY) LTD ZA (Johannesburg) participant 1˙107˙324.00
3    OSLO UNIVERSITETSSYKEHUS HF NO (OSLO) participant 840˙125.00
4    CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS FR (PARIS) participant 656˙910.00
5    NATIONAL CENTER FOR TUBERCULOSIS AND LUNG DISEASES JSC GE (TBILISI) participant 646˙016.00
6    ACADEMISCH ZIEKENHUIS LEIDEN NL (LEIDEN) participant 612˙563.00
7    ANAXOMICS BIOTECH SL ES (BARCELONA) participant 428˙250.00
8    TES2A EUROPE CONSULTING AND BUSINESS DEVELOPMENT SL ES (SANT QUIRZE DEL VALLES) participant 339˙260.00
9    LIONEX GMBH DE (BRAUNSCHWEIG) participant 124˙905.00

Map

 Project objective

Tuberculosis (TB) is a chronic, life-threatening infectious disease which poses a tremendous challenge for physicians, researchers and Health Systems, which treatment is long, based only on the drug susceptibility of the responsible infective strain and very costly in drug-resistant cases (MDR-TB). The European Region still has the highest prevalence of MDR-TB in the world. Host-Directed Therapies (HDT) have been recently proposed to shorten treatment length and by to improve the patients’ outcomes while not increasing the risk of generating drug resistance. As hyperinflammation is responsible of the lung damage associated to patients’ worse outcomes and sequelae, one of the approaches is to add an HDT with anti-inflammatory effect to the current drug regimen to cure the patients faster while having less permanent lung damage. Because TB has a wide range of clinical forms and severity stages, any therapeutic regimen needs to be studied in clinical trials (CT) as its benefit might differ among patients. No individualized personalized medicine is possible without stratifying the patients by integrating pathogen and host factors that will predict the course of the disease and the response to the intervention. SMA-TB objectives are: • To evaluate in a CT the potential impact of aspirin (an anti-inflammatory HDT) as adjunct to standard therapy for drug sensitive (DS-) and MDR-TB. This potentially will reduce tissue damage, decrease the length of the treatment and the risk of bad outcomes. • To identify and clinically validate host and pathogen biomarkers for further selection according to their relevance in terms of their ability to predict TB course and outcomes and response to treatment thanks to data science protocol. • To generate a medical algorithm to stratify patients using network-based mathematical modelling for predicting the course of the disease and its response to the intervention, to be applied during clinical management to improve and personalize TB

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SMA-TB" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SMA-TB" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers

Read More  

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More  

HAP2 (2020)

Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired Pneumonia

Read More